For your patients ≥6 years of age with moderate to severe PsO and ≥12 years of age with moderate to severe HS
Frank, real patient with HS on COSENTYX, and Elizabeth, real patient with PsO
and PsA on COSENTYX, were compensated for their time. Individual results may vary.
®
Choose COSENTYX (secukinumab)
first line for long-term impact